Sample: Between 2013 and 2016, what percentage, overall, of US adults tried to lose weight in the past 12 months?
AstraZeneca’s Investigational COVID-19 Prevention Drug Reduces Risk of Infection in Immunocompromised Persons
Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.
Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair
Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.
Lilly's Once-A-Week Insulin Demonstrates Safety, HbA1c Lowering Consistent with Daily Insulin
Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
SGLT2i Use and Improved QoL, Functional Capacity in Adults With HF: Daily Dose
Your daily dose of the clinical news you may have missed.
Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups
Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.